Basic | |
---|---|
Market Cap | $67.61M |
Price | $2.28 |
52 Week Range | 1.0-9.0 |
Beta | -0.614 |
Margins | |
Gross Profit Margin | 100.79% |
Operating Profit Margin | 64.04% |
Net Profit Margin | 59.38% |
Valuation (TTM) | |
P/E Ratio | -1.21 |
Price to Sales Ratio | -0.72 |
Price to Book Ratio | 1.02 |
PEG Ratio | 2.26 |
Biotechnology
Healthcare
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
66
2021-07-30
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
617 500 8080
245 Main Street, Cambridge, MA, 02142, US
0001790340